Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?
A 3-step analgesic ladder was introduced in 1986 and needs change. Surgical interventions could reduce opioid use and motivate expansion of current pain management approaches.
AMA J Ethics. 2020;22(8):E695-701. doi:
10.1001/amajethics.2020.695.
Wandy D. Hernandez-Gordon, CD(DONA), BDT(DONA), CLC, CCE(ACBE)
CHWs’ work underscores need for clinicians and organizations to respond to deeply entrenched, long-standing patterns of oppression in ways that draw upon lived experience.
AMA J Ethics. 2022;24(4):E333-339. doi:
10.1001/amajethics.2022.333.
On this episode of Ethics Talk, Zahra H. Khan, Yoshiko Iwai, and Dr Sayantani DasGupta outline how “abolition medicine” can motivate critical responses to medicine’s expressions of hyper-punitive, deeply racialized exercises of state authority.
Aminta Kouyate joins Ethics Talk to discuss her article, coauthored with Drs Nhi Tran and Monica U. Hahn: “Why Professionalism Demands Abolition of Carceral Approaches to Patients’ Nonadherence Behaviors.”